- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03055702
Using Mobile Phone Short Message Service (SMS) Reminders to Enhance Appointment Attendance in DM Patients
Using Mobile Phone Short Message Service (SMS) Reminders to Enhance Type 2 Diabetes Mellitus Appointment Attendance in a Primary Care Clinic
Study Overview
Status
Intervention / Treatment
Detailed Description
The main objective of this study is to evaluate the appointment attendance rate using SMS reminder of nurses and allied health appointments for diabetic patients, when compared to conventional telephone reminder and no reminder. We also aim at determine the factors associated with appointment attendance. Finally, we will also survey patients' acceptance and satisfaction to the SMS service.
This is a single blind randomization study. It will be carried out in Ha Kwai Chung General Outpatient Clinic.
The primary outcome of this study is to evaluate the attendance rate of each individual doctor, nurses and allied health clinic appointments for diabetic patients, as well as their overall attendance rates:
- Diabetes Complication Screening Clinic (OPAS DMCS/RDNA)
- Diabetes Nurse Intervention Clinic (OPAS DMIC/RDNI)
- DM nurse group (OPAS RDNG)
- Dietitian Counselling (OPAS DC/DG)
- Physiotherapy (OPAS PTC/PTG)
- Diabetes Doctor Session (OPAS RDR)
- Retino photo Assessment (OPAS RDO)
- Blood taking appointment (OPAS LABT)
The secondary outcomes are:
- Acceptance Rate of SMS Reminder Vs Telephone Reminder Vs no reminder
Factors associated with acceptance of SMS
- Personal Parameters: Age, sex, educational level, occupation, mobile phone models, Habit of using mobile phone service
- Disease Parameters: Number and types of comorbidity, disease control (by biochemical markers)
- Quality of Life (by SF-6D)
- Reported adverse effects of the reminder system
- Chang in biochemical markers (BMI, HbA1c, LDL-c level) 6-9 months later
Subjects who agreed to participate in this study will first receive a survey on the acceptance of SMS service. For those agree to receive SMS reminder, they will be randomized to:
- an SMS remind them to come for scheduled clinic appointment 24-72 hours before, or
- usual care with no reminder / telephone reminder.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Man Chi Dao, M.B.B.S.
- Phone Number: +85236515411
- Email: thomasmcdao@gmail.com
Study Locations
-
-
-
Kwai Chung, Hong Kong, 000
- Recruiting
- Ha Kwai Chung General Outpatient Clinic
-
Contact:
- Man Chi Dao
- Phone Number: +85236515411
- Email: thomasmcdao@gmail.com
-
Principal Investigator:
- Man Chi Dao, M.B.B.S.
-
Sub-Investigator:
- Sau Nga Fu, M.B.B.S.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- With diagnosis of type 2 diabetes
Have more than 1 clinic services appointment under RAMP-DM programme:
(e.g. blood taking, diabetic nurse individual counselling, group education, diabetic complication screening, retinal photo assessment, dietician counselling, etc)
Exclusion Criteria:
- Cannot read or receive appointment schedule on mobile phone
- Do not speak Cantonese/English or read Chinese/English
- Mentally incapacitated
- Pregnant Women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SMS group
receive a mobile phone text reminder for scheduled clinic appointment 24-72 hours before,
|
an SMS remind subjects to come for scheduled clinic appointment 24-72 hours before
|
No Intervention: Usual care group
Usual care, either telephone reminder or no reminder
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Attendance Rate of the scheduled clinic appointment
Time Frame: between booking time and appointment time, usually within 1 weeks to 16 weeks
|
Attendance Rate
|
between booking time and appointment time, usually within 1 weeks to 16 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Man Chi Dao, M.B.B.S., Resident
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KW/EX-16-104(100-10)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on Mobile phone text message reminder
-
Federal University of Minas GeraisUnknownCardiovascular DiseaseBrazil
-
Yaounde Central HospitalCIHR Canadian HIV Trials NetworkCompleted
-
Columbia UniversityNational Cancer Institute (NCI); Makerere UniversityNot yet recruiting
-
Assistance Publique - Hôpitaux de ParisCompletedType 1 DiabetesFrance
-
Sarah HufCompletedCervical Carcinoma | Cervical DysplasiaUnited Kingdom
-
Brigham and Women's HospitalUniversity of WaterlooCompleted
-
St. Louis UniversityTerminated
-
VA Puget Sound Health Care SystemCompleted
-
University of South FloridaTerminatedDiabetes, GestationalUnited States
-
Memorial Sloan Kettering Cancer CenterHackensack Meridian Health; The City College of New YorkActive, not recruitingHPV VaccinationUnited States